All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 9: Blood and nutrition
Toggle Parent Pages
Print this page
Management of adult malnutrition
Specialist infant formulas in primary care
Management of Vitamin D deficiency
Neural tube defects (prevention in pregnancy)
Prescribing medicines in renal impairment
Vitamin and mineral supplements following bariatric surgery
9.1 Anaemias and some other blood disorders
9.2 Fluid and electrolytes
9.3 Intravenous nutrition
9.4 Oral nutrition
9.5 Minerals
9.6 Vitamins
9.8 Metabolic disorders
Contact us about this page
9.1.7 Drugs used in other blood disorders
First Line
Second Line
Specialist
Hospital Only
Etranacogene dezaparvovec
- Solution for infusion vials 100 tera genome copies/10ml
Notes
- NICE TA989: Etranacogene dezaparvovec (Hemgenix) is recommended with managed access as an option for treating moderately severe or severe haemophilia B (congenital factor IX [FIX] deficiency) in adults without anti-FIX antibodies, only if the conditions in the managed access agreement for etranacogene dezaparvovec are followed (July 2024).
Exagamglogene autotemcel
- Dispersion for infusion vials 4million-13million cells/ml
Notes
- NICE TA1003: Exagamglogene autotemcel (exa-cel) (Casgevy) is recommended with managed access as an option for treating transfusion-dependent beta-thalassaemia in people 12 years and over:
- when a haematopoietic stem cell transplant (HSCT) is suitable, but a human leukocyte antigen-matched related haematopoietic stem cell donor is not available
- only if the conditions in the managed access agreement for exa-cel are followed (September 2024).
